| Autor: |
van Rijssel TI; University Medical Center Utrecht., van Thiel GJMW; University Medical Center Utrecht., Gardarsdottir H; University Medical Center Utrecht.; Utrecht University.; University of Iceland., van Delden JJM; University Medical Center Utrecht. |
| Jazyk: |
angličtina |
| Zdroj: |
The American journal of bioethics : AJOB [Am J Bioeth] 2024 Jan 05, pp. 1-11. Date of Electronic Publication: 2024 Jan 05. |
| DOI: |
10.1080/15265161.2023.2296404 |
| Abstrakt: |
Research ethics committees (RECs) evaluate whether the risk-benefit ratio of a study is acceptable. Decentralized clinical trials (DCTs) are a novel approach for conducting clinical trials that potentially bring important benefits for research, including several collateral benefits. The position of collateral benefits in risk-benefit assessments is currently unclear. DCTs raise therefore questions about how these benefits should be assessed. This paper aims to reconsider the different types of research benefits, and their position in risk-benefit assessments. We first propose a categorization of research benefits, based on the types of benefits that can be distinguished from the literature and ethical guidelines. Secondly, we will reconsider the position of collateral benefits. We argue that these benefits are not fundamentally different from other benefits of research and can therefore be included in risk-benefit assessments of DCTs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
